Semaglutide Shortage Ends As FDA Sets Deadline For Compounders
The FDA has declared the semaglutide shortage officially over, allowing copycat versions of the diabetes medication to be removed from production lines. The shortage, which lasted for two years, was caused by high demand and supply chain issues, prompting compounders to capitalize on the situation. With Novo Nordisk's flagship products back in stock, the FDA has set a deadline for compounding pharmacies to stop manufacturing copycat versions of semaglutide.
- As the pharmaceutical industry shifts towards more direct-to-consumer sales models, companies like Hims & Hers are poised to become major players in the market, forcing traditional giants like Novo Nordisk to rethink their business strategies.
- Will the FDA's decision mark a turning point for the regulatory body's ability to effectively manage supply chain disruptions and ensure access to essential medications in times of crisis?